News
🇺🇸 AmericasLatest pharmaceutical news, drug approvals, and FDA regulatory updates
Latest News
FDA Roundup: Oncology Drug Approvals in 2026
This article provides an overview of FDA oncology drug approvals in 2026, highlighting key developments and their implications for the pharmaceutical landscape.
FDA Grants Dual Approval for T-DXd in HER2+ Early Breast Cancer
The FDA has granted dual approval for T-DXd in treating HER2+ early breast cancer, marking a significant advancement in oncology. This decision has crucial implications for pharmaceutical stakeholders.
Biogen Acquires Apellis Pharmaceuticals: Market Analysis
Biogen's acquisition of Apellis Pharmaceuticals marks a significant shift in the pharmaceutical landscape. This article explores the implications for investors and business development teams.
6 Biotechs That Could Be Big Pharma’s Next M&A Target
This article analyzes six biotech companies that are potential M&A targets for big pharma, highlighting their market positions and investment implications.
Rigel Pharmaceuticals Licenses FDA-Approved Breast Cancer Drug VEPPANU
Rigel Pharmaceuticals' stock surged by 11.4% following the licensing of VEPPANU, an FDA-approved breast cancer drug. This move signals significant potential for growth in the oncology market.
FDA Policy Tracker 2026: Psychedelics Regulatory Updates
The FDA's 2026 Policy Tracker highlights significant regulatory updates for psychedelics, impacting investment and competitive strategies in pharma.
FDA Blocks Melanoma Drug Amid Confusion Under Makary Leadership
The FDA has blocked a new melanoma drug, leading to confusion under the leadership of Dr. Makary. This decision has significant implications for the pharmaceutical landscape.
Accelerating Drug Development: FDA's AI Clinical Trials RFI Guide
This guide analyzes the FDA's initiative to integrate AI into early-phase clinical trials, addressing key challenges and opportunities.
Novel Drug Approvals for 2026: Insights from the FDA
This article provides an overview of the FDA's novel drug approvals for 2026, highlighting key insights for business development teams, investors, and analysts.
BBSW AI Solution Event: Daily Roundup
The BBSW AI Solution event highlighted accelerating AI adoption across pharmaceutical drug discovery, clinical trials, and regulatory submissions, while participants identified critical challenges in data standardization, regulatory validation, and workforce development.
BBSW AI Solution Event: Biotech Innovation in US
The BBSW AI Solution event convened biotech stakeholders to explore artificial intelligence applications in drug discovery, emphasizing the need for rigorous validation, regulatory compliance, and ethical data practices as AI adoption accelerates across the US biotech sector.
BBSW AI Solution Debuts for Pharma Insights
BBSW has launched a new artificial intelligence solution designed to enhance pharmaceutical data analysis and accelerate drug discovery workflows. The platform integrates with existing pharma systems to improve research efficiency and clinical trial optimization.
DIA 2024: Regulatory Insights & Key Sessions to Watch
DIA 2024 offers pharmaceutical regulatory professionals critical updates on FDA policy, real-world evidence integration, and international harmonization. The conference features expert sessions, FDA roundtables, and extensive networking opportunities with regulatory leaders and technology vendors.
DIA 2024: What to Expect in Regulatory Affairs
DIA 2024 will focus on the evolving regulatory landscape, offering discussions on new FDA guidelines and compliance strategies. Networking opportunities with regulatory experts will be available.
DIA 2024: What to Expect at This Year's Event
DIA 2024 offers insights into regulatory updates and industry trends. Networking opportunities and sessions covering clinical trials, data management, and patient engagement will be available.
DIA 2024: What to Expect at the Regulatory Conference
DIA 2024 is a key event for regulatory professionals, offering insights into current regulatory challenges and future directions. The conference provides networking opportunities and sessions on new drug approvals, compliance, and global regulatory harmonization.
Bio-IT World Conference: Oncology Highlights - Day 1
Bio-IT World Conference Day 1 oncology sessions highlighted the transformative role of artificial intelligence, machine learning, and big data analytics in cancer research and precision medicine. Experts discussed advances in genomic data integration, digital pathology, and real-world evidence analytics while addressing critical challenges in data standardization and regulatory compliance.
BioMed Israel 2024: Key Innovations and US Partnerships
BioMed Israel 2024 represents a key opportunity for US pharmaceutical and biotech companies to engage with Israeli innovation in digital health, precision medicine, and therapeutic development. Official conference details remain preliminary; this article provides industry context on US-Israel biotech collaboration trends.
Fierce Biotech Week: Key Takeaways and Emerging Trends
Fierce Biotech Week 2026 convenes industry leaders to address critical challenges in drug development, regulatory strategy, and market access. The event features confirmed keynote speakers, panel discussions, and workshops spanning therapeutic areas including oncology, rare disease, and cell and gene therapy, with flexible in-person, virtual, and hybrid attendance options.
SCOPE X 2026: Key Takeaways and Highlights from Day 1
SCOPE X 2026 convened clinical research professionals to discuss emerging innovations in trial design, patient recruitment, and data management. The conference highlighted the importance of technological advancement and cross-sector collaboration in addressing persistent challenges in clinical trial execution.